HUTCHMED (China) reported that ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) delivered statistically significant progression free and overall survival benefits in the Phase III SAFFRON and SANOVO lung cancer trials. Regulatory filings for the combination have been accepted in Europe and Japan, following prior submissions in the US and existing approvals in China and Switzerland. The same savolitinib and TAGRISSO combination now spans late stage global data, multiple commercial...
HUTCHMED (China) has seen its share price fall sharply in recent years, even as it continues to advance its drug pipeline, which raises a straightforward question for investors who follow HUTCHMED closely. Is the current valuation of the stock well aligned with what the business is earning today and what those earnings suggest about its long term potential? Over the past 5 years the share price has declined 54.8%, which puts the focus squarely on whether the current earnings base can support...
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements — — Data selected for ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine — HONG KONG and FLORHAM PARK, N.J., Nov. 01, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (N
Tipranks Press Release.
— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® — — ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months — — SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting — — Establishes ORPATHYS® plus TAGRISSO® as an important targeted strategy to address MET-driven resistance following pro
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy — — Application supported by SAFFRON, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free and overall survival in this setting — — SAFFRON builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials — HONG KONG, SHANGHAI
Hutchmed (HMC) has dosed the first patient in the phase 1a portion of a global clinical trial of HMP
On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […]
HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.
Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.
Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.
HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfr
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to...
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. HUTCHMED will receive US$110 million upfront and...
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English — HONG KONG and FLORHAM PARK, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered in
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English — HONG KONG and FLORHAM PARK, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered in
AstraZeneca (LSE:AZN) and HUTCHMED reported results from the SANOVO Phase III trial in China evaluating Tagrisso in combination with Orpathys as a first-line treatment for certain patients with non-small cell lung cancer. The trial showed a statistically significant and clinically meaningful improvement in progression-free survival for the combination compared with Tagrisso alone in treatment-naïve patients with EGFR-mutated, MET-overexpressing non-small cell lung cancer.
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line settingHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in ChinaHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical P
Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.